Heartflow puts scenes on public subscription 300 million dollars

Heartflow has revealed plans to raise up to $ 300 million in an initial public offer (IPO).

The developer of the CAAD CAD (CAD) has presented a CAD model S-1 with the US Securities and Exchange Committee (SEC) on July 17, which resulted in determining its plans for the public.

Heartflow was set to be included on the Nasdaq Stock Exchange under the “HTFL” icon. The California -based company is seeking to evaluate $ 1.46 billion, to the collection of 300 million dollars by offering 16.7 million shares ranging between $ 17 and 18, with an increase of joint plans to provide 12.5 million shares between 15 and 17 dollars previously.

In the S-1 form, the company estimated that the current opportunity for the United States of America is to show it to analyze the Heartflow panel and the FFRCT Heartflow analysis was about $ 5 billion.

It is claimed that the Heartflow analysis is the AI’s only AI’s dedicated quantity tool. The platform, which received the Food and Drug Administration Declaration in 2022, aims to provide doctors with the ability to evaluate patients with arterial plaque accumulation more accurately (atherosclerosis).

Arteriosclerosis indicates the accumulation of fatty materials inside the coronary arteries walls. Leave without treatment, the condition can lead to a heart attack, stroke, and angina.

The next generation copy of the cardboard analysis It was launched in July 2024. Heartflow FFRCT analyzes computerized tomography (CCTA) to create detailed 3D models for the arteries. It is usually used as well as the Heartflow plate analysis, the platform tool assesses the effect of obstruction on blood flow and is immunized in FDA in 2014.

The company made profits worth $ 125.8 million in 2024, an increase of 44 % of its profits 2023, worth 87.2 million dollars. In the first quarter of 2025, profits amounted to $ 37.2 million, which correspond to 39 % in Q1 2024 revenues at $ 26.8 million.

The first half of 2025 witnessed a strong wave of Medtech public subscription activity. Beta Bionics The public subscription season started in 2025, an increase of $ 204 million, before its estimation of $ 114.4 million, with 12 million shares of its shared shares sold for $ 17 each.

Includes other MedTecs that announced MedTRONIC public subscription plans, with Plans to target public subscription After the separation of diabetes works in a new independent company, and the developer of Kestra Medical Technologies, with a planned public subscription of $ 154 million. Recently, at the back of 97 % revenue in 2023 to $ 27.2 million, a spine surgery that focuses on artificial intelligence Carlusd announced plans In June to go to public places with a list on the Nasdaq Stock Exchange.

“Heartflow Confls has been created and published on $ 300 million in public subscription” Medical hardware networkThe brand owned by Globaldata.

Information on this site was included in good faith for public media purposes only. It is not intended to reach the advice that you should depend on, and we do not provide any representation, guarantee or guarantee, whether it is explicit or implicit in relation to accurately or completing it. You must have a professional or specialized advice before taking any action based on the content on our website.